Leerink Swann Reiterates $448.00 Price Target for Regeneron Pharmaceuticals Inc

Leerink Swann Reiterates $448.00 Price Target for Regeneron Pharmaceuticals Inc


The firm presently has a "buy" rating on the biopharmaceutical company's stock. Leerink Swann's price objective indicates a potential upside of 17.11% from the company's current price.



from Biotech News